Oppenheimer analyst Jay Olson raised the firm’s price target on Biogen (BIIB) to $225 from $205 and keeps an Outperform rating on the shares. The firm says it is reviewing key considerations ahead of the company’s Q4 report, including how FY26 guidance for total revenues and adjusted EPS compares to the current consensus estimates; Leqembi uptake potential; expectations for BIIB080 Phase 2 CELIA data in mid-2026; SMA progress with HD nusinersen; pipeline readouts for litifilimab in SLE by year-end 226 and LRRK2 inhibitor BIIB122 for early-PD in 2026; updates on planned I&I expansion with new programs expected throughout 2026-2027; and BD strategy.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s litifilimab receives FDA BTD for cutaneous lupus erythematosus
- Acumen price target raised to $7 from $4 at BTIG
- Balancing Long‑Term Alzheimer’s Potential Against Near‑Term MS Headwinds: Rationale for Maintaining a Hold on Biogen
- Biogen price target raised to $185 from $180 at Citi
- Eisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb